NCT05070104View on ClinicalTrials.gov

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 30, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

November 1, 2024

Conditions
C04.588.274.476.411.307
Interventions
DRUG

CPI-613

250-1000mg/m2 -14 day cycle

DRUG

modified FFX

Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle

DRUG

Bevacizumab

5mg/kg IV

Sponsors
All Listed Sponsors
lead

Cornerstone Pharmaceuticals

INDUSTRY

NCT05070104 - CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter